Central Vein Sign: a Diagnostic Biomarker in Multiple Sclerosis

Active, not recruitingOBSERVATIONAL
Enrollment

420

Participants

Timeline

Start Date

June 11, 2020

Primary Completion Date

January 31, 2027

Study Completion Date

January 31, 2027

Conditions
Multiple Sclerosis
Interventions
DIAGNOSTIC_TEST

MRI

The study will include MRI at baseline (first study visit) and month 24 (final study visit). MRI at month 24 (end of study) will be used to determine McDonald Criteria and final review of CVS.

Trial Locations (11)

19104

University of Pennsylvania, Philadelphia

21218

Johns Hopkins University, Baltimore

44195

Cleveland Clinic Foundation, Cleveland

63130

Washington University in St. Louis, St Louis

78759

The University of Texas at Austin, Austin

80045

University of Colorado, Aurora

90048

Cedars-Sinai Medical Center, Los Angeles

90089

University of Southern California, Los Angeles

06520

Yale University, New Haven

05405

University of Vermont, Burlington

M5B1W8

St. Michael's Hospital of Unity Health Toronto, Toronto

All Listed Sponsors
collaborator

National Institute of Neurological Disorders and Stroke (NINDS)

NIH

collaborator

University of Pennsylvania

OTHER

collaborator

Cedars-Sinai Medical Center

OTHER

collaborator

National Institutes of Health (NIH)

NIH

lead

The Cleveland Clinic

OTHER